Collection of blood and tissue samples from patients with suspected or confirmed cancer
Official title: Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases
Run by National Institutes of Health Clinical Center (CC) · NCT00026884 · Data updated 2026-11-12
This study is collecting blood and tissue samples from patients with suspected or confirmed cancer to help researchers learn more about how these cancers develop and find new treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 5950 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | March 12, 1998 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT00026884 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults and minors with biopsy-proven malignant disease or those suspected of having such conditions, as well as family members of affected individuals.
✕Probably not a fit
Patients with co-morbidities that prevent surgical intervention may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study involves collecting blood and tissue samples from patients who have been diagnosed with or are suspected of having malignant diseases, particularly those affecting the genitourinary system. The samples will be stored in a tissue bank at the Urologic Oncology Branch of the National Cancer Institute (NCI) for future research. The study aims to investigate the genetic and molecular basis of these cancers to better understand their development and to identify potential therapeutic targets. By analyzing the differences between normal and tumor tissues, researchers hope to uncover critical insights into cancer pathways and treatment responses.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with genitourinary cancers.
How similar studies have gone: Other studies have shown success in understanding cancer genetics and developing targeted therapies, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Individuals with biopsy-proven malignant disease * Individuals suspected of having a malignant disease * Individuals who have or are suspected of having an inherited genitourinary malignant disorder * Participants must be \>= 2 years of age * A relative (related by blood) of an individual with a confirmed or suspected diagnosis of a malignant disease or an inherited genitourinary malignant disorder. * All participants and parents/guardians, for children younger than 18 years of age, must sign an informed consent document indicating their understanding of the investigational nature and the risks of this study before any protocol related studies are performed. EXCLUSION CRITERIA: -Individuals whose co-morbidities preclude surgical intervention.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: W. Marston Linehan, M.D. — National Cancer Institute (NCI)
- Study coordinator: Deborah A Nielsen, R.N.
- Email: deborah.nielsen@nih.gov
- Phone: (240) 760-6247
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
Side Effects and Resource Navigation Program for Cancer Patients
This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.
-
EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors
This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.
-
Hospital admissions for blood in the urine
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Predicting Immunotherapy Response from Live Tumor Biopsies
This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.